ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma

Genetic studies have established anaplastic lymphoma kinase (ALK), a cell surface receptor tyrosine kinase, as a tractable molecular target in neuroblastoma. We describe comprehensive genomic, biochemical, and computational analyses of ALK mutations across 1596 diagnostic neuroblastoma samples. ALK...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Cancer Cell
Päätekijät: Bresler, Scott C., Weiser, Daniel A., Huwe, Peter J., Park, Jin H., Krytska, Kateryna, Ryles, Hannah, Laudenslager, Marci, Rappaport, Eric F., Wood, Andrew C., McGrady, Patrick W., Hogarty, Michael D., London, Wendy B., Radhakrishnan, Ravi, Lemmon, Mark A., Mossé, Yaël P.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4269829/
https://ncbi.nlm.nih.gov/pubmed/25517749
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2014.09.019
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia